Sight Sciences (SGHT) Cash & Equivalents (2020 - 2026)

Sight Sciences has reported Cash & Equivalents for 7 years, with the latest figure at $85.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 21.89% year-over-year to $85.0 million; the trailing twelve-month figure through Mar 2026 stood at $85.0 million (down 21.89% YoY), and the FY2025 full-year result was $92.0 million, down 23.59% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $85.0 million, down from $92.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $238.6 million in Q1 2022, with the low at $85.0 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $141.9 million, with a median of $127.3 million recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 518.74% in 2022 and fell 29.86% in 2023.
• Tracing SGHT's Cash & Equivalents over 5 years: stood at $185.0 million in 2022, then dropped by 25.34% to $138.1 million in 2023, then dropped by 12.87% to $120.4 million in 2024, then retreated by 23.59% to $92.0 million in 2025, then dropped by 7.61% to $85.0 million in 2026.
• The last three Cash & Equivalents figures came in at $85.0 million (Q1 2026), $92.0 million (Q4 2025), and $92.4 million (Q3 2025), per Business Quant data.

Peer Comparison